ATE287260T1 - Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung - Google Patents

Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Info

Publication number
ATE287260T1
ATE287260T1 AT96918078T AT96918078T ATE287260T1 AT E287260 T1 ATE287260 T1 AT E287260T1 AT 96918078 T AT96918078 T AT 96918078T AT 96918078 T AT96918078 T AT 96918078T AT E287260 T1 ATE287260 T1 AT E287260T1
Authority
AT
Austria
Prior art keywords
controlled release
formulation
tablet
preformed opening
passageway
Prior art date
Application number
AT96918078T
Other languages
English (en)
Inventor
Chih-Ming Chen
Der-Yang Lee
Jianbo Xie
Aurelio Rodriguez
Original Assignee
Andrx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals Inc filed Critical Andrx Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE287260T1 publication Critical patent/ATE287260T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT96918078T 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung ATE287260T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/476,455 US5654005A (en) 1995-06-07 1995-06-07 Controlled release formulation having a preformed passageway
PCT/US1996/008869 WO1996040080A1 (en) 1995-06-07 1996-06-05 Controlled release formulation having a preformed passageway

Publications (1)

Publication Number Publication Date
ATE287260T1 true ATE287260T1 (de) 2005-02-15

Family

ID=23891918

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96918078T ATE287260T1 (de) 1995-06-07 1996-06-05 Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung

Country Status (8)

Country Link
US (1) US5654005A (de)
EP (1) EP0835102B1 (de)
JP (1) JPH11506774A (de)
AT (1) ATE287260T1 (de)
AU (1) AU710110B2 (de)
DE (1) DE69634204T2 (de)
NZ (1) NZ310099A (de)
WO (1) WO1996040080A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US6048547A (en) * 1996-04-15 2000-04-11 Seth; Pawan Process for manufacturing solid compositions containing polyethylene oxide and an active ingredient
GB9609094D0 (en) * 1996-05-01 1996-07-03 Univ Strathclyde Delivery device
EP0811374A1 (de) * 1996-05-29 1997-12-10 Pfizer Inc. Formulierung für ein Kombinationspräparat mit Cetirizin und Pseudoephedrin
US6361796B1 (en) * 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
JP4863534B2 (ja) * 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 可溶形態浸透用量送達システム
DE19729273C2 (de) * 1997-07-09 2000-08-17 Aventis Res & Tech Gmbh & Co Thermoplastische Mischung auf 1,4-alpha-D-Polyglucanbasis, Verfahren zu deren Herstellung und Verwendung
DK1017392T3 (da) 1997-09-25 2002-10-21 Bayer Ag Lægemiddel
DE19747261A1 (de) 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
WO2000025757A1 (en) * 1998-10-29 2000-05-11 Merck & Co., Inc. Sustained release delivery of highly water-soluble compounds
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
ATE433318T1 (de) * 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
CA2378829A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Sustained release drug dispersion delivery device
JP2003520759A (ja) * 1999-08-31 2003-07-08 アンドルックス ファーマスーティカルズ インコーポレーテッド 単位核を有する徐放性錠剤
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
BR0016555A (pt) 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
PT1242055E (pt) * 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
ES2270982T3 (es) * 2000-02-04 2007-04-16 Depomed, Inc. Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
WO2002036077A2 (en) * 2000-11-06 2002-05-10 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
CA2441064A1 (en) * 2001-03-16 2002-09-26 Andrx Corporation Controlled release sulfonylurea formulation
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US20030091634A1 (en) * 2001-09-14 2003-05-15 Pawan Seth Delayed release tablet of venlafaxin
WO2003026626A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
US20030224050A1 (en) * 2002-01-04 2003-12-04 Charles Chiao Drug delivery system for sustained delivery of glipizide
TW200302748A (en) * 2002-02-01 2003-08-16 Pfizer Prod Inc Osmotic delivery system
JP2005522424A (ja) 2002-02-01 2005-07-28 ファイザー・プロダクツ・インク コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態
KR100453288B1 (ko) * 2002-03-12 2004-10-21 한국화학연구원 약물의 제어 방출을 위한 스퀴즈-유형의 삼투성 약물 전달장치
MXPA04012021A (es) * 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US8293799B2 (en) * 2003-12-29 2012-10-23 Osmotica Keresleedelmo és Szolgáltató KFT Osmotic device containing a venlafaxine salt and a salt having an ion in common
US20040241252A1 (en) * 2003-05-29 2004-12-02 Abney Christopher Charles Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same
RS51934B (sr) * 2003-08-08 2012-02-29 Biovail Laboratories International Srl. Tableta bupropion hidrohlorida sa modifikovanim otpuštanjem
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
DE102004023069A1 (de) 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
EP1846040A2 (de) * 2005-01-28 2007-10-24 Collegium Pharmaceutical, Inc. Nicht ionische und nicht wässrige transportelemente zur topischen und oralen verabreichung träger-komplexierter wirkstoffe
KR100678421B1 (ko) * 2005-02-11 2007-02-02 주식회사 씨티씨바이오 염산 탐스로신 함유 방출조절 제제
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
AU2006269225B2 (en) * 2005-07-07 2011-10-06 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
EP1938842A4 (de) * 2005-09-01 2013-01-09 Eisai R&D Man Co Ltd Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
US20080241240A1 (en) * 2006-08-24 2008-10-02 Hanall Pharmaceutical Co., Ltd. Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
GB0702974D0 (en) * 2007-02-15 2007-03-28 Jagotec Ag Method and apparatus for producing a tablet
EP2074993A1 (de) 2007-12-19 2009-07-01 Biovail Laboratories International S.r.l. Venlafaxin enthaltende Filmtabletten mit modifizierter Wirkstofffreisetzung
EP2299983A4 (de) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc Stabilisierte atypische antipsychotische formulierung
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
US8901113B2 (en) 2009-09-30 2014-12-02 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
CA2991216C (en) 2010-12-22 2020-04-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
EP3444363B1 (de) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
US20140294947A1 (en) * 2011-09-16 2014-10-02 Purdue Pharma L.P. Tamper resistant immediate release formulations
ES2691982T3 (es) 2012-11-30 2018-11-29 Acura Pharmaceuticals, Inc. Liberación autorregulada de un principio activo farmacéutico
RU2015115397A (ru) 2012-12-21 2017-01-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Аморфная форма производного хинолина и способ его получения
AP2015008579A0 (en) 2013-02-05 2015-07-31 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
US9616029B2 (en) 2014-03-26 2017-04-11 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release coated reservoir solid dosage form
KR20230043234A (ko) 2014-08-28 2023-03-30 에자이 알앤드디 매니지먼트 가부시키가이샤 고순도의 퀴놀린 유도체 및 이를 제조하는 방법
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
CA2994925C (en) 2015-08-20 2023-08-29 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
CA3161153A1 (en) * 2019-11-14 2021-05-20 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0062321B1 (de) * 1981-04-03 1989-03-01 Fujisawa Pharmaceutical Co., Ltd. Cephalosporinderivate, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Präparate und ihre Ausgangsprodukte
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
JPH075457B2 (ja) * 1983-08-16 1995-01-25 ザ ウエルカム フアウンデ−シヨン リミテツド 調節された方法による有効成分の放出を可能にする医薬組成物
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4810502A (en) * 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JPH04503058A (ja) * 1989-01-30 1992-06-04 アルザ コーポレイション カルシウム拮抗体投与のための剤形
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
CA2107229C (en) * 1991-04-30 1997-07-22 Thomas A. Wheatley Taste-masked medicaments and their preparation
WO1993012765A1 (en) * 1991-12-27 1993-07-08 Merck & Co., Inc. A controlled release drug dispersion delivery device

Also Published As

Publication number Publication date
US5654005A (en) 1997-08-05
NZ310099A (en) 1999-09-29
DE69634204T2 (de) 2006-01-12
EP0835102A1 (de) 1998-04-15
AU710110B2 (en) 1999-09-16
JPH11506774A (ja) 1999-06-15
WO1996040080A1 (en) 1996-12-19
DE69634204D1 (de) 2005-02-24
AU6042796A (en) 1996-12-30
EP0835102B1 (de) 2005-01-19
EP0835102A4 (de) 2000-07-19

Similar Documents

Publication Publication Date Title
ATE287260T1 (de) Formulierung mit einer vorgeformten öffnung zur gesteuerten freisetzung
AU4989997A (en) Soluble form osmotic dose delivery system
EP0822809A4 (de) Formulierung mit gesteuerter freisetzung für wasserlöslische arzneistoffe, in der eine auslaböffnung in situ gebildet wird
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
BR0114633A (pt) Formulações farmacêuticas com liberação retardada
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
WO2004108067A3 (en) Programmed drug delivery system
DE69630375D1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
IL146818A0 (en) New formulation
ZA997727B (en) Pharmaceutical composition for application to mucosa.
MY101593A (en) Sustained release preparation.
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
DE69917866D1 (de) Bupropionhydrochlorid enthaltende Tabletten mit gesteuerter Wirkstoffabgabe
FI924419A0 (fi) Ett osmotiskt doseringssystem foer frigoerande av laekemedel i vaetskeform.
DE69726179D1 (de) Pharmazeutische suspensionssysteme
AU2001291526A1 (en) Sustained release composition containing clarithromycin
CA2085871A1 (en) A controlled release drug dispersion delivery device
CA2177772A1 (en) Pharmaceutical compositions containing irbesartan
NZ335063A (en) Immediate wettability water soluble film or water soluble layer for oral application
AU2001257107A1 (en) Taste masking coating composition
WO1996040074A3 (en) Device for releasing aggregation-stabilized, biologically active agent
CA2223014A1 (en) Controlled release formulation having a preformed passageway

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties